Standard Monitoring Frequency
Liver function tests (LFTs), including ALT, AST, alkaline phosphatase, bilirubin, and prothrombin time, should be monitored before starting tigecycline and routinely during therapy. Perform tests weekly while on treatment, with more frequent checks if abnormalities appear.[1][2]
Why Weekly Monitoring?
Tigecycline, a glycylcycline antibiotic, carries a risk of elevated liver enzymes, particularly transaminases, in 1-15% of patients depending on dose and duration. Weekly checks detect hepatotoxicity early, as elevations can occur within days to weeks. Manufacturers recommend this for IV therapy lasting over 14 days, but clinical practice applies it broadly.[1][3]
Adjustments for Risk Factors
Increase frequency to every 3-5 days in patients with:
- Pre-existing liver disease (Child-Pugh B/C).
- Concurrent hepatotoxins (e.g., other antibiotics, statins).
- Obesity or prolonged therapy (>14 days).
Discontinue if ALT/AST exceed 5x upper limit of normal or bilirubin >2x normal.[1][2]
What If Abnormalities Occur?
Mild elevations (2-5x ULN) often resolve with continued monitoring or dose reduction. Severe cases require immediate stoppage. Post-marketing data shows rare fulminant hepatitis, emphasizing prompt LFT review.[3]
Comparison to Other Antibiotics
Unlike vancomycin (daily in renal impairment, LFTs as needed), tigecycline needs stricter hepatic surveillance due to its biliary excretion. Linezolid monitoring is less frequent unless lactic acidosis suspected.[2]
[1]: Tygacil (tigecycline) Prescribing Information
[2]: Lexicomp: Tigecycline Monograph
[3]: DrugPatentWatch.com - Tigecycline Safety Profile (no patents listed for monitoring protocols)